PCDH10 is a candidate tumour suppressor gene in medulloblastoma

[1]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Evankovich,et al.  Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. , 2010, Neuro-oncology.

[3]  C. Hawkins,et al.  Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma , 2009, Current oncology.

[4]  M. Mansukhani,et al.  Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer , 2009, Genes, chromosomes & cancer.

[5]  I. Wistuba,et al.  Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.

[6]  Paul A. Northcott,et al.  Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.

[7]  J. Issa,et al.  Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. , 2008, Blood.

[8]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[9]  M. Barnes,et al.  Neurocognitive function in same-sex twins following focal radiation for medulloblastoma. , 2007, Neuro-oncology.

[10]  J. Issa,et al.  Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia , 2007, Cancer.

[11]  J. Rutka,et al.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies , 2006, Child's Nervous System.

[12]  M. Noseworthy,et al.  Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ. , 2006, Neuro-oncology.

[13]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Putti,et al.  Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation , 2006, Oncogene.

[15]  T. Sugimura,et al.  Identification of 20 genes aberrantly methylated in human breast cancers , 2005, International journal of cancer.

[16]  A. Goldstein,et al.  Retrospective family study of childhood medulloblastoma , 2005, American journal of medical genetics. Part A.

[17]  S. Scherer,et al.  Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling , 2004, Oncogene.

[18]  Amar Gajjar,et al.  Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Ellison,et al.  What's new in neuro-oncology? Recent advances in medulloblastoma. , 2003, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[20]  J. Drake,et al.  Medulloblastoma in a Child with Rubenstein-Taybi Syndrome: Case Report and Review of the Literature , 2001, Pediatric Neurosurgery.

[21]  J. Rutka,et al.  Perspectives in pediatric neurosurgery , 2000, Child's Nervous System.

[22]  J. Rutka,et al.  Molecular Insight into Medulloblastoma and Central Nervous System Primitive Neuroectodermal Tumor Biology from Hereditary Syndromes: A Review , 2000, Neurosurgery.

[23]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[24]  H. Lai,et al.  Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. , 2011, American journal of obstetrics and gynecology.

[25]  J. Uhm.  Medulloblastoma Comprises Four Distinct Molecular Variants , 2011 .

[26]  P. Northcott,et al.  Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. , 2010, Neurosurgical focus.

[27]  M. Guan,et al.  High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. , 2010, Neoplasma.

[28]  R. Arceci.  Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations , 2010 .

[29]  G. Rao.  The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog–Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog–Treated Cerebellar Neural Precursors , 2010 .

[30]  David Hogg,et al.  Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.

[31]  J. Rutka,et al.  Pediatric brain tumors: a contemporary prospectus. , 2000, Clinical neurosurgery.

[32]  P. Morin,et al.  beta-catenin signaling and cancer. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[33]  A. Yap,et al.  The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. , 1998, Cancer investigation.